Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury

Laboratory Investigation

Volumn 90, Issue 4, 2010, Pages 566-576

  Hindryckx, Pieter ^a   Waeytens, Anouk ^a   Laukens, Debby ^a   Peeters, Harald ^a   Van Huysse, Jacques ^b   Ferdinande, Liesbeth ^b   Carmeliet, Peter ^c,d   De Vos, Martine ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Experimental colitis; Inflammatory bowel disease; Intestinal mucosal hypoxia; Placental growth factor; Vascular endothelial growth factor

Indexed keywords

ADENOVIRUS VECTOR; DEXTRAN SULFATE; MYELOPEROXIDASE; PIMONIDAZOLE; PLACENTAL GROWTH FACTOR; RECOMBINANT PROTEIN; TRINITROBENZENESULFONIC ACID; VASCULOTROPIN;

ACUTE DISEASE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE EXACERBATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; HYPOXEMIA; INFLAMMATORY INFILTRATE; INTESTINE CELL; LEUKOCYTE; MORBIDITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SCORING SYSTEM; UPREGULATION; VASCULARIZATION; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; ANOXIA; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950364116     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.37     Document Type: Article

References (29)

1. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006;130:2060-2073. (Pubitemid 43816964) (Pubitemid 43816964)
2. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007;56:855-862.
3. Pousa ID, Maté J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest 2008;38:73-81.
4. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
5. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475.
6. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.
7. Cianfarani F, Zambruno G, Brogelli L, et al. Placental growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 2006;169:1167-1182.
8. Kolakowski Jr S, Berry MF, Atluri P, et al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg 2006;21:559-564.
9. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
10. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142.
11. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007;2:541-546.
12. Van der Sluis M, De Koning B, De Bruijn A, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-129.
13. Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-209.
14. Overbergh L, Giulietti A, Valckx D, et al. The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 2003;14:33-43.
15. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med 2007;85:1295-1300.
16. Sakuraba H, Ishiguro Y, Yamagata K, et al. Blockade of TGF-b accelerates mucosal destruction through epithelial cell apoptosis. Biochem Biophys Res Commun 2007;359:406-412.
17. Spencer AU, Yang H, Haxhija EQ, et al. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Dig Dis Sci 2007;52:1060-1070.
18. Vetuschi A, Latella G, Sferra R, et al. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2002;47:1447-1457.
19. Boismenu R, Chen Y, Chou K, et al. Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Ann Rheum Dis 2002;61(Suppl 2):19-24.
20. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004;114:1098-1106.
21. Ikeda H, Suzuki Y, Suzuki M, et al. Apoptosis is a major mode of cell death caused by ischaemia and ischaemia/reperfusion injury to the rat intestinal epithelium. Gut 1998;42:530-537.
22. Morote-Garcia JC, Rosenberger P, Nivillac NM, et al. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 2009;136:607-618.
23. Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-956.
24. Kader HA, Tchernev VT, Satyaraj E, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005;100:414-423.
25. Pousa ID, Maté J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis 2008;14:61-67.
26. Chidlow JH, Langston W, Greer JJM, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006;169:2014-2030.
27. Cooper H, Murthy SNS, Shah R, et al. Clinicopathologic study of dextran sulphate sodium experimental murine colitis. Laborat Invest 1993;69:238-249.
28. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
29. Qualls JE, Kaplan AM, van Rooijen NJ, et al. Suppression of experimental colitis by intestinal mononuclear phagocytes. Leukoc Biol 2006;80:802-815.